Repare Selling General Administrative from 2010 to 2024

RPTX Stock  USD 2.81  0.16  5.39%   
Repare Therapeutics Selling General Administrative yearly trend continues to be fairly stable with very little volatility. Selling General Administrative will likely drop to about 18.4 M in 2024. During the period from 2010 to 2024, Repare Therapeutics Selling General Administrative regression line of annual values had r-squared of  0.64 and arithmetic mean of  9,849,955. View All Fundamentals
 
Selling General Administrative  
First Reported
2019-03-31
Previous Quarter
8.3 M
Current Value
6.4 M
Quarterly Volatility
2.8 M
 
Covid
Check Repare Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Repare Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 2.8 M, Interest Income of 13.8 M or Depreciation And Amortization of 1.8 M, as well as many indicators such as Price To Sales Ratio of 5.71, Dividend Yield of 0.0 or PTB Ratio of 1.52. Repare financial statements analysis is a perfect complement when working with Repare Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Repare Therapeutics Correlation against competitors.
For more information on how to buy Repare Stock please use our How to Invest in Repare Therapeutics guide.

Latest Repare Therapeutics' Selling General Administrative Growth Pattern

Below is the plot of the Selling General Administrative of Repare Therapeutics over the last few years. It is Repare Therapeutics' Selling General Administrative historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Repare Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Selling General Administrative10 Years Trend
Slightly volatile
   Selling General Administrative   
       Timeline  

Repare Selling General Administrative Regression Statistics

Arithmetic Mean9,849,955
Geometric Mean4,690,116
Coefficient Of Variation122.50
Mean Deviation10,134,874
Median1,774,000
Standard Deviation12,065,781
Sample Variance145.6T
Range32M
R-Value0.80
Mean Square Error55.9T
R-Squared0.64
Significance0.0003
Slope2,164,030
Total Sum of Squares2038.2T

Repare Selling General Administrative History

202418.4 M
202333.8 M
202232.6 M
202126.2 M
202014.3 M
20195.4 M
20182.9 M

About Repare Therapeutics Financial Statements

Repare Therapeutics investors use historical fundamental indicators, such as Repare Therapeutics' Selling General Administrative, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Repare Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Selling General Administrative33.8 M18.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Repare Stock Analysis

When running Repare Therapeutics' price analysis, check to measure Repare Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repare Therapeutics is operating at the current time. Most of Repare Therapeutics' value examination focuses on studying past and present price action to predict the probability of Repare Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repare Therapeutics' price. Additionally, you may evaluate how the addition of Repare Therapeutics to your portfolios can decrease your overall portfolio volatility.